US opioid-class REMS will include certifications
This article was originally published in Scrip
Executive Summary
The US FDA's vision of a risk evaluation and mitigation strategy (REMS) for long-acting opioid class of products includes prescriber and pharmacist education and certifications, as well as a patient-prescriber agreement.